Danish pharmaceutical company Novo Nordisk A/S (CPH:NOVO-B) (NYSE:NVO) said on Friday that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended once-weekly Sogroya (somapacitan) for the treatment of growth hormone deficiency in children and adolescents.
Growth hormone deficiency in children can lead to short stature and other growth-related health problems. Current treatment typically requires daily injections of growth hormone, which can be burdensome and affect adherence, especially in children.
The positive CHMP opinion represents a step forward in providing a simpler treatment option for children as young as three years old.
The recommendation was based on data from the phase 3 REAL4 study, which demonstrated the efficacy of once-weekly subcutaneous injection of Sogroya compared to once-daily Norditropin (somatropin). The European Commission will review the opinion, with a final decision expected in the coming months.
Sogroya received approval from the US Food & Drug Administration (FDA) in April 2023. Subject to approval by the European Commission, it is anticipated to be available in some European countries starting in Q4 2023.
AbbVie's ELAHERE receives full US FDA approval
Johnson & Johnson's OPSYNVI receives US FDA approval
Outlook Therapeutics receives positive CHMP opinion for ONS-5010 in wet AMD treatment
Human Immunology Biosciences receives ODD from FDA for felzartamab
Eton Pharmaceuticals acquires PKU GOLIKE, expanding rare disease portfolio
Vertex receives FDA clearance for VX-407 Investigational New Drug Application for ADPKD
Phanes Therapeutics receives FDA Fast Track designation for PT886
Bio-Thera Solutions signs new licensing agreement with SteinCares
FDA accepts resubmission of Citius Pharmaceuticals, Inc's BLA for LYMPHIR
GSK Plc reports positive Phase III Jemperli data for endometrial cancer
ImmVira receives FDA Fast Track designation for MVR-T3011 IT